NOS3 and Alzheimer disease: Since various treatments are available that maintain or increase endothelial NO bio-availability, B6.2xTg; B6.eNOS transgenic mice were examined at 18 months age (~ 56 human-year equivalents [44]) to better simulate the age when familial AD becomes apparent in humans.